Recent insights into the use of immune checkpoint inhibitors in gastric cancer

Figueiredo, Céu

doi:10.1097/j.pbj.0000000000000162

Cited by 4 publications

(3 citation statements)

References 85 publications

(280 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in recent years, programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors have been used to manage advanced gastric cancer treatment. Unfortunately, clinical trials demonstrate that treatments with nivolumab and pembrolizumab (PD-1 inhibitors) or avelumab (PD-L1 inhibitor) show a response rate of 22–27% in terms of survival [ 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers

et al. 2023

View full text Add to dashboard Cite

Gastric cancer, the second most common cause of death worldwide, is characterized by poor prognosis and low responsiveness to chemotherapy. Indeed, multidrug resistance, based mainly on cellular and molecular factors, remains one of the most limiting factors of the current approach to gastric cancer (GC) therapy. We employed a comprehensive gene expression analysis through data mining of publicly available databases to assess the role of the signal transducer and activator of transcription 3 (STAT3) in gastric cancer drug efficiency. It has been proposed that gastric cancer cells are less sensitive to these drugs because they develop resistance to these agents through activating alternative signalling pathways responsible for overcoming pharmacological inhibition. Our study evaluated the hypothesis that activating STAT3 signalling in response to cisplatin reduces the reaction to the drug. Consistent with this hypothesis, inhibition of interleukin 6 (IL-6)/STAT3 in combination therapy with cisplatin prevented both STAT3 activation and more lethality than induction by a single agent. The data suggest that the IL-6/STAT3 axis block associated with cisplatin treatment may represent a strategy to overcome resistance.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Specifically, immune checkpoint inhibitors in locally advanced and metastatic gastric cancer patients act by mediating the blockage of the programmed cell death protein 1 (PD-1)/PD-L1 axis. They are preferred in standard chemotherapy-refractory cases or those who have been previously treated with two or more chemotherapeutic regimens [9].…”

Section: Introductionmentioning

confidence: 99%

First-Line Systemic Therapy Outcomes in western population with Locally Advanced and Metastatic Gastric Cancer - A Systematic Review

Marupuru¹,

Arku²,

Axon³

et al. 2023

Preprint

View full text Add to dashboard Cite

Globally, gastric cancer is a major cause of cancer mortality, with a 5-year survival rate of 32% for locally advanced and metastatic gastric cancer. This systematic literature review summarized the clinical, safety, and humanistic outcomes associated with systemic regimens given as first line therapy for locally advanced and metastatic gastric cancer. The search included articles published in English in PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and the American Society of Clinical Oncology meeting library, from inception to April 2022. Phase II and III randomized controlled trials conducted among western populations diagnosed with stage III and IV locally advanced and metastatic gastric cancer were included. Two investigators independently reviewed the studies, conducted data extraction, and assessed risk of bias in accordance with PRISMA guidelines. Twenty-four randomized controlled trials totaling 8,705 patients were included. Median overall survival ranged from 5.0-13.1 months, median progression-free survival ranged from 2.0-7.7 months, and objective response ranged from 13.0-64.1%. Two studies reported higher quality of life outcomes. Grade 3 and 4 adverse events were reported in most studies. Improvement in clinical outcomes can be seen in recently published randomized controlled trials for locally advanced and metastatic gastric cancer.

show abstract

“…Immune activation by immune checkpoint inhibitors seems to have a more durable clinical benefit than traditional chemotherapy in locally A/MGC and a lower incidence of adverse events [18,19]. The ATTRACTION-2 phase III clinical trials l assessed Nivolumab or placebo in metastatic gastric cancer patients and showed significant overall survival that persisted over time [20].…”

Section: Introductionmentioning

confidence: 99%

First-Line Systemic Therapy Outcomes in Western Population with Locally Advanced and Metastatic Gastric Cancer—A Systematic Review

Marupuru,

Arku,

Axon

et al. 2023

Gastroenterology Insights

View full text Add to dashboard Cite

Globally, gastric cancer is a major cause of cancer mortality, with a 5-year survival rate of 32% for locally advanced and metastatic gastric cancer (A/MCG). This systematic literature review summarized the clinical, safety, and humanistic outcomes associated with systemic regimens administered as a first-line therapy for A/MGC. The search included articles published in English in PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and the American Society of Clinical Oncology meeting library, from inception to April 2022. Phase II and III randomized controlled trials (RCTs) conducted among western populations diagnosed with stage III and IV A/MGC were included. Two investigators independently reviewed the studies, conducted data extraction, and assessed risk of bias in accordance with PRISMA guidelines. Twenty-four randomized controlled trials totaling 8705 patients were included. Median overall survival ranged from 5.0 to 13.1 months, median progression-free survival ranged from 2.0 to 7.7 months, and objective response ranged from 13.0 to 64.1%. Two studies reported high quality-of-life outcomes. Grade 3 and 4 adverse events were reported in most studies. This review provides a comprehensive overview of first-line systemic therapy outcomes in western populations with A/MGC. With the evolving treatment landscape of A/MGC, an improvement in clinical outcomes can be seen in recently published RCTs with immunotherapies. The potential of new targeted treatments and immunotherapies may present more favorable forthcoming options for treating A/MGC.

show abstract

Recent insights into the use of immune checkpoint inhibitors in gastric cancer

Cited by 4 publications

References 85 publications

Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers

Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers

First-Line Systemic Therapy Outcomes in western population with Locally Advanced and Metastatic Gastric Cancer - A Systematic Review

First-Line Systemic Therapy Outcomes in Western Population with Locally Advanced and Metastatic Gastric Cancer—A Systematic Review

Contact Info

Product

Resources

About